Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B

Journal of Clinical Gastroenterology

Volumn 48, Issue 10, 2014, Pages 889-895

  Kang, Seong Hee ^a   Yim, Hyung Joon ^a   Kim, Hae Rim ^a   Kang, Keunhee ^a   Suh, Sang Jun ^a   Lee, Hyun Jung ^a   Yoon, Eileen L ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yeon, Jong Eun ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MIDDLE AGED; MUTATION; TIME; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84916236913     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/mcg.0000000000000066     Document Type: Article

References (34)

1. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86: 1143-1150.
2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337: 1733-1745.
3. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science. 1993;262: 369-370.
4. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(suppl 1): 100-107.
5. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125: 1714-1722.
6. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet. 2001;358: 718-723.
7. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000;32: 129-134.
8. Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology. 1998;28: 1669-1673.
9. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55: 1488-1495.
10. Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: Current approaches and potential strategies including pegylated interferon. Liver Int. 2010;30: 657-668.
11. Choe WH, Hong SP, Kim BK, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther. 2009;14: 985-993.
12. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther. 2011;16: 77-87.
13. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50: 661-662.
14. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49: S174-S184.
15. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44: 703-712.
16. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43: 1385-1391.
17. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int. 2012;6: 531-561.
18. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57: 167-185.
19. Son CY, Ryu HJ, Lee JM, et al. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int. 2012;32: 1179-1185.
20. Heo NY, Lim YS, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53: 449-454.
21. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41: 1391-1398.
22. Park JW, Kim HS, Seo DD, et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18: E475-e481.
23. Seo SY, Kim IH, Sohn JY, et al. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. Intervirology. 2014;57: 8-16.
24. Lim YS, Lee JY, Lee D, et al. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56: 2941-2947.
25. Chae HB, Kim MJ, Seo EG, et al. High efficacy of adefovir and entecavir combination therapy in patients with nucleosiderefractory hepatitis B. Korean J Hepatol. 2012;18: 75-83.
26. Yim HJ, Seo YS, Yoon EL, et al. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): A 2-year follow-up randomized controlled trial. Liver Int. 2013;33: 244-254.
27. Lampertico P, Viganò M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42: 1414-1419.
28. Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12: 355-362.
29. Yuen MF, Fung J, Wong DK, et al. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9: 256-264.
30. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60: 247-254.
31. van Bö mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virusmonoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51: 73-80.
32. van Bö mmel F, Zö llner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44: 318-325.
33. Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: Reflections on battles over a decade. Clin Mol Hepatol. 2013;19: 195-209.
34. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. J Hepatol. 2012;56: 520-526.